company background image
VVY logo

Vivoryon Therapeutics ENXTAM:VVY Stock Report

Last Price

€1.79

Market Cap

€46.7m

7D

-7.0%

1Y

-76.0%

Updated

08 Dec, 2024

Data

Company Financials +

Vivoryon Therapeutics N.V.

ENXTAM:VVY Stock Report

Market Cap: €46.7m

VVY Stock Overview

A clinical stage biopharmaceutical company, engages in the research, development, and commercialize small molecule-based medicines. More details

VVY fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health5/6
Dividends0/6

Vivoryon Therapeutics N.V. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Vivoryon Therapeutics
Historical stock prices
Current Share Price€1.79
52 Week High€9.93
52 Week Low€0.41
Beta2.02
11 Month Change-18.82%
3 Month Change-10.72%
1 Year Change-75.97%
33 Year Change-89.20%
5 Year Change-65.04%
Change since IPO-91.05%

Recent News & Updates

We Think Vivoryon Therapeutics (AMS:VVY) Needs To Drive Business Growth Carefully

Dec 05
We Think Vivoryon Therapeutics (AMS:VVY) Needs To Drive Business Growth Carefully

Recent updates

We Think Vivoryon Therapeutics (AMS:VVY) Needs To Drive Business Growth Carefully

Dec 05
We Think Vivoryon Therapeutics (AMS:VVY) Needs To Drive Business Growth Carefully

Here's Why We're Watching Vivoryon Therapeutics' (AMS:VVY) Cash Burn Situation

May 28
Here's Why We're Watching Vivoryon Therapeutics' (AMS:VVY) Cash Burn Situation

Here's Why We're Watching Vivoryon Therapeutics' (AMS:VVY) Cash Burn Situation

May 04
Here's Why We're Watching Vivoryon Therapeutics' (AMS:VVY) Cash Burn Situation

Companies Like Vivoryon Therapeutics (AMS:VVY) Are In A Position To Invest In Growth

Sep 02
Companies Like Vivoryon Therapeutics (AMS:VVY) Are In A Position To Invest In Growth

Here's Why We're Not Too Worried About Vivoryon Therapeutics' (AMS:VVY) Cash Burn Situation

Jan 26
Here's Why We're Not Too Worried About Vivoryon Therapeutics' (AMS:VVY) Cash Burn Situation

Companies Like Vivoryon Therapeutics (AMS:VVY) Are In A Position To Invest In Growth

Sep 16
Companies Like Vivoryon Therapeutics (AMS:VVY) Are In A Position To Invest In Growth

We Think Vivoryon Therapeutics (AMS:VVY) Can Afford To Drive Business Growth

May 10
We Think Vivoryon Therapeutics (AMS:VVY) Can Afford To Drive Business Growth

Is Vivoryon Therapeutics N.V.'s (AMS:VVY) Shareholder Ownership Skewed Towards Insiders?

Mar 11
Is Vivoryon Therapeutics N.V.'s (AMS:VVY) Shareholder Ownership Skewed Towards Insiders?

We're Hopeful That Vivoryon Therapeutics (AMS:VVY) Will Use Its Cash Wisely

Jan 14
We're Hopeful That Vivoryon Therapeutics (AMS:VVY) Will Use Its Cash Wisely

Shareholder Returns

VVYNL BiotechsNL Market
7D-7.0%0.8%2.1%
1Y-76.0%4.4%7.6%

Return vs Industry: VVY underperformed the Dutch Biotechs industry which returned 4.4% over the past year.

Return vs Market: VVY underperformed the Dutch Market which returned 7.6% over the past year.

Price Volatility

Is VVY's price volatile compared to industry and market?
VVY volatility
VVY Average Weekly Movement11.6%
Biotechs Industry Average Movement7.6%
Market Average Movement3.9%
10% most volatile stocks in NL Market7.2%
10% least volatile stocks in NL Market2.3%

Stable Share Price: VVY's share price has been volatile over the past 3 months compared to the Dutch market.

Volatility Over Time: VVY's weekly volatility has decreased from 28% to 12% over the past year, but is still higher than 75% of Dutch stocks.

About the Company

FoundedEmployeesCEOWebsite
199715Frank Weberwww.vivoryon.com

Vivoryon Therapeutics N.V., a clinical stage biopharmaceutical company, engages in the research, development, and commercialize small molecule-based medicines. Its pipeline products target toxic pyroglutamate-Abeta (pGlu-Abeta), which inhibits the production of pGlu-Abeta. The company’s lead product candidate is PQ912, a nanomolar QPCT inhibitor that has completed Phase IIb clinical trials for use in the treatment of Alzheimer’s disease.

Vivoryon Therapeutics N.V. Fundamentals Summary

How do Vivoryon Therapeutics's earnings and revenue compare to its market cap?
VVY fundamental statistics
Market cap€46.66m
Earnings (TTM)-€31.18m
Revenue (TTM)n/a

-12.9x

P/S Ratio

-1.5x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
VVY income statement (TTM)
Revenue-€3.62m
Cost of Revenue-€525.00k
Gross Profit-€3.09m
Other Expenses€28.09m
Earnings-€31.18m

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

Dec 10, 2024

Earnings per share (EPS)-1.20
Gross Margin85.50%
Net Profit Margin861.46%
Debt/Equity Ratio0%

How did VVY perform over the long term?

See historical performance and comparison